ESPE Abstracts (2023) 97 P1-132

ESPE2023 Poster Category 1 Growth and Syndromes (75 abstracts)

One-year growth response and cost-effectiveness to Human recombinant growth hormone in girls with Turner Syndrome: Results from a large Egyptian retrospective study

Amany Ibrahim 1 , Abeer Atef 1 , Nora Badawi 1 , Sahar Yassin 2 & Eatemad Helmy 3

1Pediatric Department, DEMPU, Faculty of Medicine, Cairo University, cairo, Egypt. 2Community Medicine and Public Health, Faculty of Medicine, Cairo University., Cairo, Egypt. 3Mataria Teaching Hospital, General Organization for teaching Hospitals and Institutes (GOTHI), Cairo, Egypt

FDA licensed the use of human recombinant growth hormone (hGH) in girls with Turner Syndrome (TS) in 1997 as short stature is a consistent feature of this syndrome.

Objective: we aimed to assess our 1-year experience of treating short girls with TS, to calculate their growth velocity, to analyze the patients’ characteristics and to investigate the possible factors that might affect their height gain.

Methods: we studied a cohort of 190 girls with TS. Anthropometric measurements were reported regularly for one year. The cost in dollars for height gain in (cm) in one year was identified using Markov cost-effectiveness simulation model.

Results: This retrospective study included 190 girls with TS (their age at the start of the study was 11.99±3.24 years. Mosaic TS represent 47 patients (24.7 %) & 60% (114) of total patients were dysmorphic, 70% of our cases had 45+X0 karyotyping & 24.7% had 45+X/46+XX karyotyping & 5.3% had other different karyotyping (45, X/47, XXX). Peak GH by Clonidine and Insulin 5.62 ± 4.82 and 8.69 ± 2.39 respectively. The predicted adult height of the first visit, last visit & delta predicted adult height between the first & last visit in our study (143.33 ± 6.59, 145.45 ± 4.67 & 2.12 ± 2.06 respectively). The cost in dollars for height gain in (cm) in one year was identified to be 99.07 ± 37.83 dollars/cm, the height gain in 1 year 5.04 ± 1.62 cm/year costed a total of 499.34 ± 190.71 dollars with hGH dose of 0.04 ± 0.01 mg/kg/d (1.36 ± 0.52 mg/day). Positive correlation between height gain during the study period and duration of therapy and height at presentation SDS (P-values = 0.027 and 0.015 respectively) and negative correlations with age at diagnosis and dose of hGH (mg/kg/d) (P- values = 0.006 and 0.02 respectively) were detected. Conclusion: hGH is effective in height and growth velocity improvement of short girls with TS. Height at presentation SDS and hGH dose seem to be effective predictors for height gain in our girls with TS.

Volume 97

61st Annual ESPE (ESPE 2023)

The Hague, Netherlands
21 Sep 2023 - 23 Sep 2023

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.